^†Itch reduction responders at Day 3 with RINVOQ 15 mg. Data from MEASURE UP 1 and 2: replicate, phase 3 randomised, double-blind, placebo-controlled studies to evaluate the efficacy and safety of upadacitinib monotherapy vs placebo in adolescents and adults with moderate-to-severe AD. Upadacitinib 15 mg n=281 and 276; 30 mg n=285 and 282; placebo n=281 and 278. Co-primary endpoints were EASI 75 and vIGA-AD of 0 or 1 with ≥2 grades of reduction at Week 16 (NRI-C). Co-primary and all secondary endpoints were met (p≤0.001 for all vs placebo).

^§Superior EASI 75 vs dupilumab at Week 16 (p=0.006), multiplicity controlled. Data from HEADS UP: a phase 3 randomised, double blind, double-dummy, active-controlled study comparing the safety and efficacy of upadacitinib 30 mg OD to dupilumab 300 mg Q2W in adults with moderate-to-severe AD. Upadacitinib 30 mg n=348; dupilumab 300 mg n=344. Primary endpoint was EASI 75 at Week 16. Primary endpoint and all secondary endpoints were met (p=0.006 and p<0.001 respectively vs dupilumab).

*Superiority was demonstrated in the HEADS UP trial using the RINVOQ 30 mg dose in adults aged 18 – 75 years. The 30 mg dose is licensed for use in adults aged 18 – 64 years. For patients aged 65 years or older the recommended dose is 15 mg once daily.

AD, atopic dermatitis; EASI, Eczema Area and Severity Index; EASI 75, ≥75% reduction in EASI; OD, once daily; Q2W, once every two weeks; RIN, RINVOQ; vIGA-AD 0/1, Validated Investigator’s Global Assessment for AD of clear or almost clear.